Research Advances In Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Elevated cholesterol levels, especially elevated Low density lipoprotein cholesterol levels, is an independent risk factor for incidence of arteriosclerotic cardiovascular disease. Low density lipoprotein cholesterol reduction is seen as a key factor for reducing the risk of arteriosclerotic cardiovascular disease. By regulating the low density lipoprotein receptor, proprotein convertase subtilisin/kexin type 9 affects Low density lipoprotein cholesterol metabolism, lowers levels of Low density lipoprotein cholesterol and becomes a novel target site of hypercholesterolemia therapy. Therefore varieties of proprotein convertase subtilisin/kexin type 9 inhibitors has emerged. Recently, different pathways of proprotein convertase subtilisin/kexin type 9 inhibitors have been explored, monoclonal antibody,as the most rapidly developing one, will become a promising lipid-lowering agent.